Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Eletriptan | Drug | 40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in headache pain severity | 1, 2, 4, and 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Functional impairment | 1, 2, 4, and 24 hours | |
| Work Productivity Questionnaire | Week 10 | |
| Time Loss |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Irvine | California | 92618 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Week 10 |
| Subject Preference Questionnaire | Week 10 |
| Global Evaluation | Week 10 |
| Subject Satisfaction Scale | Week 10 |
| Associated Symptoms | 1, 2, 4, and 24 hours |
| Use of Rescue Medication | Week 10 |
| Adverse events | Week 10 |
| Vital signs | Week 10 |
| Physical examination | Week 10 |
| Newport Beach |
| California |
| 92660-2452 |
| United States |
| Pfizer Investigational Site | San Francisco | California | 94109 | United States |
| Pfizer Investigational Site | Plantation | Florida | 33324 | United States |
| Pfizer Investigational Site | St. Petersburg | Florida | 33710 | United States |
| Pfizer Investigational Site | Tampa | Florida | 33609 | United States |
| Pfizer Investigational Site | Marietta | Georgia | 30067 | United States |
| Pfizer Investigational Site | South Bend | Indiana | 46601 | United States |
| Pfizer Investigational Site | Milford | Massachusetts | 01757 | United States |
| Pfizer Investigational Site | Chesterfield | Missouri | 63017 | United States |
| Pfizer Investigational Site | Springfield | Missouri | 65804 | United States |
| Pfizer Investigational Site | Greensboro | North Carolina | 27403 | United States |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | United States |
| Pfizer Investigational Site | Eugene | Oregon | 97401 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | United States |
| Pfizer Investigational Site | Alexandria | Virginia | 22304 | United States |
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C115647 | eletriptan |
Not provided
Not provided
Not provided